https://scholars.lib.ntu.edu.tw/handle/123456789/551114
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Liang C.-C. | en_US |
dc.contributor.author | CHEN-HUA LIU | en_US |
dc.contributor.author | Chung C.-S | en_US |
dc.contributor.author | Lin C.-K | en_US |
dc.contributor.author | TUNG-HUNG SU | en_US |
dc.contributor.author | HUNG-CHIH YANG | en_US |
dc.contributor.author | CHUN-JEN LIU | en_US |
dc.contributor.author | PEI-JER CHEN | en_US |
dc.contributor.author | DING-SHINN CHEN | en_US |
dc.contributor.author | JIA-HORNG KAO | en_US |
dc.date.accessioned | 2021-03-09T01:47:37Z | - |
dc.date.available | 2021-03-09T01:47:37Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0022-1899 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928911806&doi=10.1093%2finfdis%2fjiu630&partnerID=40&md5=e42e8e8f039f3b41c4296fe5bf9094f3 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/551114 | - |
dc.description.abstract | Background. Clinical implications of persistent alanine aminotransferase (ALT) elevation and associated factors in chronic hepatitis C (CHC) patients who achieved undetectable hepatitis C virus (HCV) RNA during pegylated interferon plus ribavirin (peg-IFN/RBV) therapy remain unknown. Methods. A total of 1113 CHC patients with undetectable HCV RNA during peg-IFN/RBV therapy were enrolled. Baseline characteristics associated with persistent on-treatment ALT elevation (POAE), and its impact on treatment outcomes, were investigated. Results. Of 1113 CHC patients, 254 (22.8%) had POAE. Among patients with HCV genotype 1 (HCV-1) who had complete early virologic response (EVR) and received 48 weeks of therapy, patients with POAE had a lower rate of sustained virologic response (SVR) than those without POAE (44.1% vs 74.0%; P =. 0002). Multivariate analyses showed that body mass index ? 27 kg/m2, ALT level ?3 times the upper limit of normal, aspartate aminotransferase to platelet ratio index score ?1.5, hepatic fibrosis ?F3, and hepatic steatosis ?S2 were independent factors associated with POAE after viral clearance. Conclusions. POAE is common in CHC patients during therapy. HCV-1 patients with POAE have a lower SVR rate to 48-week therapy if they achieve complete EVR. Advanced hepatic fibrosis, obesity, and steatosis are factors associated with POAE in these patients. ? 2014 The Author. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. | en_US |
dc.publisher | Oxford University Press | en_US |
dc.relation.ispartof | Journal of Infectious Diseases | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; peginterferon alpha2a; peginterferon alpha2b; ribavirin; virus RNA; alanine aminotransferase; alpha interferon; antivirus agent; macrogol derivative; peginterferon alpha2a; peginterferon alpha2b; recombinant protein; ribavirin; virus RNA; adult; Article; body mass; chronic hepatitis C; cohort analysis; controlled study; disease association; disease severity; drug response; fatty liver; female; Hepatitis C virus genotype 1; human; human cell; liver disease; liver fibrosis; major clinical study; male; persistent on treatment alanine aminotransferase elevation; prevalence; priority journal; reference value; scoring system; thrombocyte count; treatment duration; treatment outcome; treatment response; viral clearance; aged; blood; chronic hepatitis C; drug combination; enzymology; fatty liver; genetics; Hepacivirus; isolation and purification; liver cirrhosis; metabolism; middle aged; pathology; virology; Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | - |
dc.title | Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1093/infdis/jiu630 | - |
dc.identifier.pmid | 25387585 | - |
dc.identifier.scopus | 2-s2.0-84928911806 | - |
dc.relation.pages | 1429-1436 | en_US |
dc.relation.journalvolume | 211 | en_US |
dc.relation.journalissue | 9 | en_US |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Microbiology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0003-3622-9707 | - |
crisitem.author.orcid | 0000-0002-6747-7941 | - |
crisitem.author.orcid | 0000-0003-3864-9895 | - |
crisitem.author.orcid | 0000-0002-6202-0993 | - |
crisitem.author.orcid | 0000-0001-8316-3785 | - |
crisitem.author.orcid | 0000-0001-7791-6154 | - |
crisitem.author.orcid | 0000-0002-2442-7952 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。